2019 Future of Contact Dermatitis R&D Pipeline Drugs and Companies- Analysis of Global Contact Dermatitis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Contact Dermatitis treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Contact Dermatitis pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Contact Dermatitis pipeline companies from advancing their products into Phase 3 or Phase 4.
Contact Dermatitis Report Description
The H1 2019 pipeline review report on Contact Dermatitis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Contact Dermatitis pipeline compounds.
The Contact Dermatitis pipeline guide presents information on all active drugs currently being developed for Contact Dermatitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Contact Dermatitis pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Contact Dermatitis drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Contact Dermatitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Contact Dermatitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Contact Dermatitis pipeline report includes
REASONS TO BUY
Contact Dermatitis Report Description
The H1 2019 pipeline review report on Contact Dermatitis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Contact Dermatitis pipeline compounds.
The Contact Dermatitis pipeline guide presents information on all active drugs currently being developed for Contact Dermatitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Contact Dermatitis pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Contact Dermatitis drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Contact Dermatitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Contact Dermatitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Contact Dermatitis pipeline report includes
- An overview of Contact Dermatitis disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Contact Dermatitis pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Contact Dermatitis pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Contact Dermatitis pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL CONTACT DERMATITIS PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Contact Dermatitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Contact Dermatitis pipeline, H1- 2019
3.5 Mechanism of Action wise Contact Dermatitis Pipeline Candidates
4. BRICKELL BIOTECH INC CONTACT DERMATITIS PIPELINE DETAILS
4.1 Brickell Biotech Inc Business Profile
4.2 Brickell Biotech Inc Contact Dermatitis Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. EDESA BIOTECH INC CONTACT DERMATITIS PIPELINE DETAILS
5.1 Edesa Biotech Inc Business Profile
5.2 Edesa Biotech Inc Contact Dermatitis Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. HAPTEN SCIENCES INC CONTACT DERMATITIS PIPELINE DETAILS
6.1 Hapten Sciences Inc Business Profile
6.2 Hapten Sciences Inc Contact Dermatitis Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. ILIAD BIOTECHNOLOGIES LLC CONTACT DERMATITIS PIPELINE DETAILS
7.1 ILiAD Biotechnologies LLC Business Profile
7.2 ILiAD Biotechnologies LLC Contact Dermatitis Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. NEUROCYCLE THERAPEUTICS CONTACT DERMATITIS PIPELINE DETAILS
8.1 NeuroCycle Therapeutics Business Profile
8.2 NeuroCycle Therapeutics Contact Dermatitis Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. SIGNUM DERMALOGIX INC CONTACT DERMATITIS PIPELINE DETAILS
9.1 Signum Dermalogix Inc Business Profile
9.2 Signum Dermalogix Inc Contact Dermatitis Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. LATEST CONTACT DERMATITIS DRUG PIPELINE DEVELOPMENTS, 2019
11. APPENDIX
11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL CONTACT DERMATITIS PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Contact Dermatitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Contact Dermatitis pipeline, H1- 2019
3.5 Mechanism of Action wise Contact Dermatitis Pipeline Candidates
4. BRICKELL BIOTECH INC CONTACT DERMATITIS PIPELINE DETAILS
4.1 Brickell Biotech Inc Business Profile
4.2 Brickell Biotech Inc Contact Dermatitis Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. EDESA BIOTECH INC CONTACT DERMATITIS PIPELINE DETAILS
5.1 Edesa Biotech Inc Business Profile
5.2 Edesa Biotech Inc Contact Dermatitis Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. HAPTEN SCIENCES INC CONTACT DERMATITIS PIPELINE DETAILS
6.1 Hapten Sciences Inc Business Profile
6.2 Hapten Sciences Inc Contact Dermatitis Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. ILIAD BIOTECHNOLOGIES LLC CONTACT DERMATITIS PIPELINE DETAILS
7.1 ILiAD Biotechnologies LLC Business Profile
7.2 ILiAD Biotechnologies LLC Contact Dermatitis Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. NEUROCYCLE THERAPEUTICS CONTACT DERMATITIS PIPELINE DETAILS
8.1 NeuroCycle Therapeutics Business Profile
8.2 NeuroCycle Therapeutics Contact Dermatitis Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. SIGNUM DERMALOGIX INC CONTACT DERMATITIS PIPELINE DETAILS
9.1 Signum Dermalogix Inc Business Profile
9.2 Signum Dermalogix Inc Contact Dermatitis Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. LATEST CONTACT DERMATITIS DRUG PIPELINE DEVELOPMENTS, 2019
11. APPENDIX
11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information
